Phenylboronic-acid-based nanocomplex as a feasible delivery platform of immune checkpoint inhibitor for potent cancer immunotherapy
出版年份 2020 全文链接
标题
Phenylboronic-acid-based nanocomplex as a feasible delivery platform of immune checkpoint inhibitor for potent cancer immunotherapy
作者
关键词
Cancer immunotherapy, Phenylboronic ester, Immune checkpoint inhibitor, Nanocomplex, Antitumor therapy
出版物
JOURNAL OF CONTROLLED RELEASE
Volume 330, Issue -, Pages 1168-1177
出版商
Elsevier BV
发表日期
2020-11-17
DOI
10.1016/j.jconrel.2020.11.024
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- A Bioinspired Platform for Effective Delivery of Protein Therapeutics to the Central Nervous System
- (2019) Di Wu et al. ADVANCED MATERIALS
- Photothermal therapy mediated by phase-transformation nanoparticles facilitates delivery of anti-PD1 antibody and synergizes with antitumor immunotherapy for melanoma
- (2019) Ni Zhang et al. JOURNAL OF CONTROLLED RELEASE
- Bioresponsive Protein Complex of aPD1 and aCD47 Antibodies for Enhanced Immunotherapy
- (2019) Qian Chen et al. NANO LETTERS
- NanoRNP Overcomes Tumor Heterogeneity in Cancer Treatment
- (2019) Qi Liu et al. NANO LETTERS
- Tumor targeting via EPR: Strategies to enhance patient responses
- (2018) Susanne K. Golombek et al. ADVANCED DRUG DELIVERY REVIEWS
- Bioinspired Diselenide-Bridged Mesoporous Silica Nanoparticles for Dual-Responsive Protein Delivery
- (2018) Dan Shao et al. ADVANCED MATERIALS
- Advances in transformable drug delivery systems
- (2018) Quanyin Hu et al. BIOMATERIALS
- Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors
- (2018) Kristian M. Hargadon et al. INTERNATIONAL IMMUNOPHARMACOLOGY
- PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression
- (2018) Haidong Tang et al. JOURNAL OF CLINICAL INVESTIGATION
- Sequentially Responsive Therapeutic Peptide Assembling Nanoparticles for Dual-Targeted Cancer Immunotherapy
- (2018) Keman Cheng et al. NANO LETTERS
- Cancer immunotherapy using checkpoint blockade
- (2018) Antoni Ribas et al. SCIENCE
- In situ formed reactive oxygen species–responsive scaffold with gemcitabine and checkpoint inhibitor for combination therapy
- (2018) Chao Wang et al. Science Translational Medicine
- Fundamental Mechanisms of Immune Checkpoint Blockade Therapy
- (2018) Spencer C. Wei et al. Cancer Discovery
- Andrographolide-loaded polymerized phenylboronic acid nanoconstruct for stimuli-responsive chemotherapy
- (2017) Jinhwan Kim et al. JOURNAL OF CONTROLLED RELEASE
- PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity
- (2017) Vikram R. Juneja et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Cancer acidity: An ultimate frontier of tumor immune escape and a novel target of immunomodulation
- (2017) Veronica Huber et al. SEMINARS IN CANCER BIOLOGY
- Dual-pH Sensitive Charge-reversal Nanocomplex for Tumor-targeted Drug Delivery with Enhanced Anticancer Activity
- (2017) Qing Zhou et al. Theranostics
- Glycosylation engineering of therapeutic IgG antibodies: challenges for the safety, functionality and efficacy
- (2017) Yusuke Mimura et al. Protein & Cell
- Immune-related adverse events with immune checkpoint blockade: a comprehensive review
- (2016) J.M. Michot et al. EUROPEAN JOURNAL OF CANCER
- Nanotechnology for protein delivery: Overview and perspectives
- (2016) Mikyung Yu et al. JOURNAL OF CONTROLLED RELEASE
- Self-sufficing H2O2-responsive nanocarriers through tumor-specific H2O2 production for synergistic oxidation-chemotherapy
- (2016) Junjie Li et al. JOURNAL OF CONTROLLED RELEASE
- Tumor Microenvironment-Mediated Construction and Deconstruction of Extracellular Drug-Delivery Depots
- (2016) Quanyin Hu et al. NANO LETTERS
- Surface charge critically affects tumor penetration and therapeutic efficacy of cancer nanomedicines
- (2016) Hong-Xia Wang et al. Nano Today
- PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
- (2016) Weiping Zou et al. Science Translational Medicine
- Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
- (2015) J. Naidoo et al. ANNALS OF ONCOLOGY
- Immune Checkpoint Blockade in Cancer Therapy
- (2015) Michael A. Postow et al. JOURNAL OF CLINICAL ONCOLOGY
- Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy
- (2015) Abhisek Swaika et al. MOLECULAR IMMUNOLOGY
- Principles of nanoparticle design for overcoming biological barriers to drug delivery
- (2015) Elvin Blanco et al. NATURE BIOTECHNOLOGY
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- PD-L1 Expression in Triple-Negative Breast Cancer
- (2014) E. A. Mittendorf et al. Cancer Immunology Research
- Acidity Generated by the Tumor Microenvironment Drives Local Invasion
- (2013) V. Estrella et al. CANCER RESEARCH
- Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
- (2012) Julie R. Brahmer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tailoring nanocarriers for intracellular protein delivery
- (2011) Zhen Gu et al. CHEMICAL SOCIETY REVIEWS
- pH-Responsive Nanoparticles for Drug Delivery
- (2010) Weiwei Gao et al. MOLECULAR PHARMACEUTICS
- The safety and side effects of monoclonal antibodies
- (2010) Trevor T. Hansel et al. NATURE REVIEWS DRUG DISCOVERY
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started